Food & Drug Law Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Bavarian Nordic

Progress reported in smallpox vaccine development

Bavarian Nordic noted particular progress has been made to date on their safe, third generation smallpox vaccine program in the U.S.:

1) The U.S. Food and Drug Administration (FDA) granted Bavarian Nordic an Investigational New Drug (IND) application for Imvamune to enter further clinical trials. The first-ever trial with Imvamune in persons with atopic disorders (ie. eczema) is underway.

2) Results from a phase II study showed that Imvamune has an excellent safety profile at all three dose levels tested. All study volunteers sero-converted after...

• View Other Issues of Food & Drug Law Weekly
  
• View Other NewsRx Publications